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Abstract
Group A Streptococcus pyogenes (GAS) is a human pathogen that commonly 
causes superficial infections such as pharyngitis, but can also lead to systemic and 
fatal diseases. GAS infection remains to be a major threat in regions with insuf-
ficient medical infrastructures, leading to half a million deaths annually worldwide. 
The pathogenesis of GAS is mediated by a number of virulence factors, which func-
tion to facilitate bacterial colonization, immune evasion, and deep tissue invasion. 
In this review, we will discuss the mechanism of molecular interaction between 
the host protein and virulence factors that target the fibrinolytic system, including 
streptokinase (SK), plasminogen-binding group A streptococcal M-like protein 
(PAM), and streptococcal inhibitor of complement (SIC). We will discuss our cur-
rent understanding, through structural studies, on how these proteins manipulate 
the fibrinolytic system during infection.
Keywords: hemolytic Streptococcus, streptokinase, plasminogen-binding 
streptococcal M protein, streptococcal inhibitor of complement, plasmin,  
host-pathogen coevolution
1. Introduction
Group A Streptococcus (GAS) is a strict human pathogen that leads to diverse 
clinical manifestations, ranging from superficial infections, such as pharyngitis, 
to severe cases of streptococcal toxic shock syndrome and necrotizing fasciitis 
mainly in children and young adults [1]. GAS infection can also lead to a range 
of post-streptococcal autoimmune sequelae such as acute rheumatic fever, 
rheumatic heart disease, and acute glomerulonephritis [2, 3]. Life-threatening 
systemic GAS infection is more prevalent in, but not limited to, regions with 
insufficient medical infrastructures and is estimated to cause more than half 
a million deaths annually worldwide [4, 5]. Through coevolution, GAS has 
perfected its ability to manipulate the host fibrinolytic system for invasion. In 
human, the plasminogen/plasmin (Plg/Plm) system plays a key role in fibrinoly-
sis, tissue remodeling, and wound healing [6–9]. This review aims to focus on the 
current understanding on molecular mechanisms adopted by GAS to hijack the 
host Plg/Plm system during infection.
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2. The plasminogen/plasmin system
The early observation that streptococci stimulate fibrinolysis by Dr. William 
S. Tillett in 1933 [10] had triggered the subsequent discoveries on how streptococci 
manipulated the fibrinolytic system to facilitate blood clot dissolution [11]. The 
actual protein responsible for the clot lysis is in fact a constituent of the human 
plasma, instead of the bacteria, and is not fibrinolytic until activated by the strep-
tococcal protein named streptokinase (SK) [12, 13]. This human lytic factor is 
plasmin (Plm), an activated form of plasminogen (Plg).
2.1 Structure of Plg
Plasmin (Plm) is a plasma serine protease responsible for many physiological 
functions such as cell migration [14], wound healing [15], inflammation [16], and 
prohormone processing [17]. Plm circulates in an inactive zymogen form called 
plasminogen (Plg).
Primarily synthesized and secreted by the liver [18], native Plg is a 89–92 kDa 
glycoprotein comprising of seven domains: an N-terminal PAN-apple domain 
(PAp), followed by five homologous kringle domains (KR-1 to KR-5) and a serine 
protease domain (SP) (Figure 1a) [19, 20]. The PAp domain is important for main-
taining a compact conformation (closed) in the circulation [21]. Each KR domain 
has a lysine-binding site (LBS) that consists of the Asp-X-Asp/Glu motif (except 
KR-3 which has the Asp-X-Lys mutation) that recognizes and binds to surface lysine 
or arginine residues, such that the KR domains facilitate the binding of Plg and Plm 
to substrates and targets (such as fibrin and cell surface receptors) which leads to 
the conformational change from close to open. SP is the catalytic domain. In the 
zymogen form, residues His603, Asp646, and Ser741 (also called the catalytic triad) 
adopt an inactive configuration.
2.2 Physiological activation of Plg
In mammals, the two key physiological Plg activators are tissue-type (tPA) and 
urokinase-type (uPA) Plg activators (Figure 1b). Activation of Plg requires its co-
localization with the activators; the expression of these activators is regulated both 
spatially and temporally in vivo [22–24]. Thus, Plm plays a key role in fibrinolysis intra-
vascularly on the surface of fibrin clots in the presence of tPA and cellular migration 
and tissue remodeling extravascularly in the presence of uPA bound on cell surfaces.
Upon binding to the targets, Plg adopts an open conformation. The activa-
tion loop, which is obstructed by the linker between KR-3 and KR-4 in the closed 
conformation, becomes exposed. The activation bond (Arg561-Val562) is then pro-
teolytically cleaved by uPA and tPA [25, 26]. The nascent N-terminal Val562 moves 
by 11.6 Å forming a salt bridge with Asp740; this triggers a series of conformational 
changes and thus allows the formation of a functional substrate binding site and 
catalytic pocket (Figure 1c). In Plm, the heavy chain (N-terminal domains, 63 kDa) 
and the light chain (SP domain, 25 kDa) are linked together by two disulfide bonds, 
between Cys558-Cys566 and Cys548-Cys666.
Serine protease inhibitors (termed serpins [27]) play a key regulatory role to 
ensure that there is no aberrant activation of Plg nor free Plm in the circulation. 
Under physiological conditions, the activity of plasminogen activators is modulated 
by their specific plasminogen activator inhibitors (PAI-1 and PAI-2) (Figure 1b) 
[28]. Active Plm which is not physically immobilized is removed immediately from 
the circulation by Plm-specific inhibitor α2-antiplasmin (α2-AP) [29, 30].
3Toward Better Understanding on How Group A Streptococcus Manipulates Human…
DOI: http://dx.doi.org/10.5772/intechopen.88182
3. Streptokinase
3.1 Structure and function of SK
SK is secreted by GAS as a 47 kDa protein and consists of three homologous 
domains, termed α, β, and γ, held together by flexible linker loops. Each domain 
adopts a β-grasp fold consisting of 4–5-stranded β sheets and a central α-helix or 
a coiled coil [31]. The interaction between Plg/Plm and SK is evolutionarily con-
served and strictly species specific [32, 33]. SK variants secreted by GAS isolated 
from different species (e.g., from human, pig, and horse) are incapable of any 
cross-species reactivity and therefore are predicted to share not only low sequence 
identity but also low structural homology [32].
Figure 1. 
The structure and function of human plasminogen (Plg). (a) Cartoon representation of the X-ray crystal 
structure of Plg in the closed conformation (PDB ID: 4DUR) [21]. The seven domains of Plg are the PAN-
apple (PAp), kringles 1–5 (KR-1 to KR-5), and serine protease (SP) domains, shown in different colors. (b) 
The Plg/Plm system. Plg is converted to active plasmin (Plm) by activators, urokinase plasminogen activator 
(uPA) and tissue plasminogen activator (tPA), on fibrin or receptor. The activators are regulated by serine 
protease inhibitors (serpins), plasminogen activator inhibitors (PAI-1 and PAI-2). Plm, upon released from 
its site of action, is inhibited by α2-antiplasmin (α2-AP). (c) Conformational change in the SP domain 
during Plm formation. Superposition of the SP domains of Plg (PDB ID: 4DUR) [21] and Plm (PDB ID: 
3UIR) [94] reveals the insertion and formation of a salt bridge between Val562 and Asp740 in Plm (left panel). 
This interaction leads to the rearrangement of catalytic triad His603, Asp646, and Ser741 (right panel) into an 
active conformation.
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The X-ray crystallography studies on the binary complex of Plm SP domain 
(μPlm) and SK reveal that SK wraps around the SP domain forming a horse-
shoe-shaped structure [31, 34] (Figure 2) and further superposition of the 
full-length closed Plg with the μPlm-SK structures suggests that the interaction 
between SK and Plg can occur with Plg, which remains in its closed conforma-
tion without any steric clashes (Figure 2) [35]. This observation provides 
fundamental insights to the mode of Plg activation by SK, as discussed in the 
next section.
SK is not a protease, nor it activates Plg by proteolytically cleaving the activation 
loop as uPA or tPA mentioned above. It forms a 1:1 stoichiometric complex with Plg 
through a rapid binding reaction, with an association rate of 5.4 × 107 M−1 s−1 [36]. 
Binding of SK to free Plg results in the formation of catalytically active Plg (Plg*) 
(Figure 3). The SK-Plg* binary complex [37, 38] cleaves Plg, either in closed or open 
conformation, to form Plm.
The Plm generated has a much higher (~57,000-fold) affinity for SK than Plg 
(KD 11 pM and 624 nM, respectively), such that the Plg in the SK-Plg* complex 
would be replaced by Plm to form the final and irreversible SK-Plm complex 
(Figure 3) [39, 40]. The inhibitory capacity of α2-AP reduces significantly with 
a ~10,000-fold lower affinity for the SK-Plm complex than Plm (rate constant of 
1.4 × 102 and 5.4 × 107 M−1 s−1, respectively) [36, 41]; accordingly, GAS infection 
could potentially generate an unregulated pericellular proteolytic (i.e., Plm) activity 
within the host.
3.2 Plg activation by SK
How does SK activate Plg without cleaving the activation loop? The current 
model suggests that the N-terminal Ile1 residue of SK inserts into the binding 
cleft of Val562 in the SP domain and forms a salt bridge with Asp740. Accordingly, 
it induces a conformational change and formation of a functional catalytic site 
[42–44]. This “molecular sexuality” mechanism of cofactor-induced zymogen 
activation is also reported in the activation of prothrombin-2 by staphylocoagulase 
from Staphylococcus aureus [45].
Figure 2. 
Crystal structure of SK-μPlg and in silico docking model of SK-Plg encounter complex (left panel). Structure of 
SK-μPlg (Plg SP domain) complex (PDB ID: 1BML) [31]. SK α, β, and γ domains are colored blue, pink and 
green, respectively, whereas μPlg is shown in orange. (Middle panel) Superposition of the SK-μPlg structure 
and (right panel) full-length Plg generate the structural model of SK-Plg encounter complex. This model 
suggests that the SK can bind to closed Plg without any steric interference. Dashed circle highlights the proposed 
Plg substrate binding region (250-loop) in the β domain of SK.
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The activation loop of Plg has evolved, via negative selection, to be a poor sub-
strate of Plm [46], to minimize the risks of autoactivation. Binding to SK, however, 
changes the shape of the substrate binding pocket. In doing so, SK-Plg* and SK-Plm 
becomes highly specific in the binding and cleavage of the Plg activation loop [47], 
and this leads to a total deregulation of the fibrinolytic system.
Lastly, how does SK-Plg* or SK-Plm access the activation loop of Plg which is 
shielded in the closed conformation as previously discussed? Published data sug-
gested that SK mediates a conformational change in the substrate Plg. Specifically, 
the substrate binding site of SK-Plm is situated at the tip of the protruding 250-loop 
region (residues Ala251-Ile264) of SK β domain (Figure 2) [34]. Mutation studies 
reveal that residues Arg253, Lys256, and Lys257 of the same 250-loop can also bind 
simultaneously to the substrate Plg via its LBS of KR-5 domain [48], forming a ter-
nary complex [31, 49, 50]. Thus, it is foreseeable that SK β domain peels KR-5 away 
from the PAp domain which leads to the formation of an open Plg with its activation 
loop exposed.
Further, SK has a 20-fold higher affinity for Plg in the open conformation, pre-
sumably due to additional interactions with other KR domains [40, 51]. Specifically, 
the C-terminal Lys414 of SK γ domain has been shown to interact with KR-4 LBS 
[52, 53]. Apart from Lys414, other Lys residues located at the β and γ domains might 
also be involved in binding to other KRs; together they promote a remarkably 
high-affinity interaction between SK and Plg/Plm in their open conformation [54]. 
However, without any structural data on the co-complexes of the relevant domains, 
the exact mechanism of the LBS-dependent interactions remains to be speculative.
3.3 Classification of streptokinase
All invasive GAS strains express SK to enhance dissemination [55, 56] and 
colonization within the host [57]. Interestingly, the SK alleles are polymorphic and 
can be subdivided into two phylogenetic lineages based on the highly variable β 
domain [38], namely, cluster 1 (SK1) and cluster 2 (SK2) (Figure 4a) [38, 58, 59]. 
The sequence identities of α, β, and γ domains between GAS strains are 77, 55, and 
84%, respectively [60]. GAS from different clusters show different properties in Plg 
activation, receptor expression, and receptor binding.
Figure 3. 
Mechanism of SK-mediated Plg activation. (1) The first catalytic (named trigger) cycle is initiated by the 
binding of free Plg to SK and the generation of the proteolytically active SK-Plg* complex. (2) SK-Plg* activates 
free Plg substrate to Plm. (3) Plm displaces Plg in the SK-Plg* complex to form the final and irreversible 
SK-Plm complex. (4) In the second catalytic (named bullet) cycle, the SK-Plm activator complex converts free 
Plg to Plm at a fast rate.
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SK1-Plg complex is enzymatically active (Figure 4b) but has been shown 
to be susceptible to α2-AP inhibition [37]. Furthermore, SK1-Plg can bind to 
fibrinogen (Fg) and form the Fg-SK1-Plg ternary complex without any changes 
to the enzymatic activity [37]. SK1-Plg binds directly to Plg receptors such as 
Figure 4. 
(a) Allelic variants of streptokinase (SK) from GAS. Sequence alignment of cluster 1, 2a and 2b SK clinical 
isolates. α, β, and γ domain regions are colored blue, pink, and green, respectively. “*,” “:,” and “.” denote for 
strictly conserved, strongly similar, and weakly similar residues, respectively. Alignment was performed using 
the Clustal Omega multiple sequence alignment server (EMBL-EBI). Protein sequence GenBank accession 
numbers NZ131, ACI61887.1; NS210, AGA54152.1; NS53, AGA54154.1; NS931, AGA54153.1; 5448, AFJ44175.1; 
NS696, AFJ44174.1; AP53, AGA54155.1; NS223, AGA54156.1; NS455, AGA54157.1; and NS88.2, AGA54158.1. 
(b) Cartoon illustration of the functional differences of SK clusters. Left: Cluster 1 and 2a SK can directly 
activate Plg in a 1:1 complex and localize to the bacterial cell surface via plasminogen receptors or indirectly via 
fibrinogen-binding M protein. Cluster 1 SK-Plm complex is susceptible to α2-AP inhibition. Cluster 2a SK-Plm 
and cell surface-bound complexes are α2-AP resistant. Right: Cluster 2b SK must first form a ternary complex 
with fibrinogen (Fg) and Plg before binding onto cell surface via PAM or M protein. Unless bound to PAM, 
SK-Plg-Fg is inhibited by α2-AP.
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glyceraldehyde-3-phosphate dehydrogenase and enolase, whereas Fg-SK1-Plg binds 
to M protein receptor such as M1.
SK2 is further subdivided into two clusters—SK2a and SK2b. Like SK1, SK2a 
expresses M protein and other Plg receptors, and the SK2a-Plg* complex is enzy-
matically active. One striking difference is that both SK2a-Plg* and SK2a-Plm are 
resistant to α2-AP inhibition. SK2b on the other hand is co-expressed with a specific 
Plg receptor called plasminogen-binding group A streptococcal M-like protein 
(PAM, see next section) [38, 59]. SK2b has a lower affinity for Plg (30-fold lower 
than SK1 and SK2a) [37], and the SK2b-Plg complex is enzymatically inactive. 
Thus, Plg activation by SK2b is strictly limited to the bacterial cell surface [61]. 
Upon formation of the quaternary complex of PAM-SK2b-Plg-Fg, this complex is 
resistant to α2-AP (Figure 4b).
The polymorphism and functional differences between the SK variants result in 
different physiopathology of streptococcal infection [59]. For example, the PAM-
expressing SK2b strains where Plm activity is restricted to the cell surface are able to 
sustain much longer-lasting skin infections [37, 62].
4. Plg-binding group A streptococcal M-like protein (PAM)
M protein is the major virulence determinant of GAS [63]. It belongs to a 
family of dimeric coiled-coil surface-associated proteins. Under the electron 
microscope, it appears as a fibrillar coat on the bacteria surface [64]. The protein 
sequence of M proteins is highly variable especially in the first 50 residues at the 
N-terminus, known as the hypervariable region (HVR). Strain typing based on 
HVR sequence has identified more than 250 M subtype to date [65]. The variable 
region confers affinity to different host molecules, such as Fg [66], immuno-
globulin [67], complement factor H [68], etc. There has been a number of reviews 
published on the sequence pattern and function of the M protein family [64, 69] 
and therefore will not be covered in the current paper. Here, we will focus on the 
structure and function of PAM, which is a specific Plg receptor that mediates Plg 
activation by SK2b.
4.1 Structure of PAM
PAM is encoded by the emm gene situated in the multiple gene activator (mga) 
regulon. The mga regulon contains varying number of emm or emm-like genes and 
forms the basis of the five different emm patterns (type A-E). PAM-positive GAS 
strains are exclusively emm pattern D [70, 71].
PAM has the overall domain architecture of an M protein, which includes a 
hypervariable region (HVR) at the N-terminus followed by variable A and B repeat 
domains and the conserved C and D domains and an anchor region (Figure 5a). 
In the precursor protein, there is a signal sequence that precedes the HVR and is 
removed upon secretion. The anchor region consists of an LPTXG motif that is 
responsible for sortase-mediated crosslinking of the C-terminus to the cell wall 
peptidoglycan [64].
To date, no binding target or function has been assigned to the HVR region. 
However, as this region extends the farthest from the cell surface, it might serve as 
a hypermutatable decoy which promotes GAS evasion from the host immunity as 
observed for the HVR of M1 and M5 proteins [72].
The A repeat domain consists of up to two tandem repeats termed a1 and a2. 
The a1a2 repeats each harbor a conserved Plg-binding motif consisting of an 
arginine-histidine dipeptide (termed the RH motif). PAM variants differ mainly 
Staphylococcus and Streptococcus
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Figure 5. 
(a) PAM variants from emm pattern D GAS strains. Sequence alignment of PAM variants shown is divided 
into three classes: I, II, and III. RH motifs in a1 and a2 repeats are highlighted in red, and the three-residue 
insertions between a1 and a2 in class III PAM are highlighted in blue. For clarity, residues before signal 
sequence and after sortase sequence were removed. “*,” “:,” and “.” denote strictly conserved, strongly similar, 
and weakly similar residues, respectively. Alignment was performed using the Clustal Omega multiple 
sequence alignment server (EMBL-EBI). Protein sequence GenBank accession numbers AP53, CAA80222.1; 
NS13, AAQ64521.2; NS59, AAQ64518.2; NS10, AAQ64516.2; NS50.1, AAQ64519.3; AlaB49, AEQ25265.1; 
NS88.2, AAQ64526.2; NS223, AAQ64524.2; NS455, AAQ64527.2; NS1133, AAQ64517.2; NS265,  
AAQ64525.2; NS221, AAZ66743.1; NS253, AAQ64523.2; NS53, AAQ64522.3; and NS32, AAQ64520.2. (b) 
Cartoon illustration of the conformational change of PAM and Plg binding. It is proposed that the N-terminal 
portion of PAM (from HVR to B domain) is largely disordered and transforms to a helical structure upon 
binding to Plg. The structural change serves to enhance the intermolecular interactions.
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in the HVR and A repeat region [71] and can be divided into three classes based on 
the A domain arrangements, namely, I, II, and III (Figure 5a). All classes have the 
a2 repeat, class I has both a1a2 repeats, class II only has a2, and class III has both 
a1a2 repeats as in class I, but the repeats are separated by a three-residue insertion. 
In bacterial strains such as PAMNS265 and PAMNS32, the second RH motif is mutated 
to Arg-Tyr and Gly-His, respectively (Figure 5a). Despite these variations, all PAM 
bind to human Plg with high affinities [71, 73, 74].
Based on NMR studies [74], the structure of the HVR and A domain is predomi-
nantly disordered, and the binding to Plg results in a major conformational change 
and formation of α-helical structures (Figure 5b). This observation was further 
supported by experimental data published in a recent study [75], where it is revealed 
that the conformation switch can be detected even without binding to Plg, and the 
alternation between disordered and a dimeric α-helical structure occurs in a temper-
ature-dependent manner, similar to the M1 protein reported previously [76]. This 
observation could be explained by a conformation sampling of the flexible domains.
Other than the aforementioned dynamic and dimeric interaction at the 
N-terminal HVR and A domains, the current structure model of PAM is a coiled-
coil dimer, which is stabilized via the C and D domains’ interaction [74]. It is 
proposed that at least two C domains are required for a stable dimer formation. 
However, PAMNS455, one of the smallest PAM variants identified to date, contains 
only one C domain (Figure 5a). While it has been shown that PAMNS455 has high 
affinity for Plg [71], the question remains if and how PAMNS455 maintains the 
dimeric assembly.
4.2 Binding mechanism of PAM to Plg
PAM binds to both Plg and Plm directly with high affinity (KD of ~1 nM) [77, 78] 
through the RH motifs in the A repeat region to Plg KR2 domain (Figure 6) [79].  
Figure 6. 
X-ray crystal structure of angiostatin (KR1-KR2) and VEK-30 complex (PDB ID 2DOI). VEK-30 (magenta), 
a peptide derived from PAM AP53, binds to KR2 (brown) primarily by its RH (R101 and H102) motif (sticks) 
interacting with the LBS residues D219 and E221 (inset). Together, R101, H102, and E104 form a lysine isostere 
that is recognized by the LBS of KR2. KR1 (light-blue) does not play a role in the complex formation [80].
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Based on the crystal structures of the a1 repeat-KR2 binary complex, the side 
chains of the RH motif residues Arg101 and His102 form a pseudo-lysine moiety 
(called the lysine isostere) and bind to the LBS of KR2 [79, 80]. Peripheral 
residues of the RH motif such as Asp91, Glu93, Leu97, Lys98, and Glu104 mediate 
further intermolecular interaction via binding to residues of KR2 outside the 
LBS, namely, Tyr200, Arg220, Arg234, and Trp235 [80]. These additional interac-
tions play important roles in stabilization of the complex. Of these residues, 
Tyr200 and Arg220 are unique to KR2, accordingly; these residues may drive 
the specificity of the A repeats toward the KR2 domain. In doing so, PAM is 
expected to bind not only tightly to Plg but also without competing with SK 
binding [80]. Further structural studies would be required to validate this 
hypothesis.
Outside the A repeats-KR2 binding interface, there are many questions remained 
to be addressed regarding the interaction between Plg and PAM. For instance, both 
a1 and a2 were shown to bind KR2 [81], but would a single PAM monomer bind to 
two Plg? Further, KR2 in closed Plg is inaccessible. How does PAM bind to KR2? 
Does it induce a conformational change of Plg prior to the complex formation [78]? 
Furthermore, the N-linked glycosylation of Plg at KR3 in Plg glycoform I reduces 
its affinity for PAM [82]; does KR3, which does not have a functional LBS, mediate 
exosite(s) interaction with PAM?
5. Streptococcal inhibitor of complement (SIC)
Streptococcal inhibitor of complement (SIC) is a 31-kDa secreted virulence 
factor found in M1 and M57 GAS serotypes. SIC is named after its inhibitory 
function of complement-mediated cell lysis. SIC binds to complement system 
regulators such as histidine-rich glycoprotein, clusterin, and membrane attack 
complex C5b-C9 (Figure 7a) [83]. Subsequent research revealed that SIC also 
binds to antimicrobial peptides [84, 85], extracellular histones [86], fibrin [87], 
thrombin [87], and plasminogen [87]. Accordingly, the physiological role of SIC 
is to manipulate the host defense system for infection and invasion. Of particular 
interest to the current review is that it inhibits the fibrinolytic system through 
binding to Plg [87].
5.1 Structure and function of SIC
SIC consists of an N-terminal signal peptide that is cleaved upon secretion; the 
mature form has a short repeat region followed by three tandem repeats of about 
30 residues each (Figure 7b). The three-dimensional structure of SIC is currently 
unknown, and there is no apparent sequence identity with proteins in the database 
such as Pfam.
Additional to its well-known roles in suppressing the host defense system, 
SIC has been shown to modulate the fibrinolytic system [87]. It was proposed 
that SIC inhibits SK-mediated Plg activation. Specifically, SIC-positive GAS 
entrapped in the fibrin clot allows its survival for much longer than the SIC-
negative strain. The entrapped bacteria colonize before its dissemination from 
the primary infection sites.
SIC is expressed in the early growth phase of M1 GAS; its role, which is to 
temporally regulate the activity of SK, is only reported in a recent study. It was 
shown that the Plg-binding motif(s) in SIC is located at the C-terminal 200 resi-
dues which presumably binds the Plg KR domains [87]. Significantly, although 
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SIC does not bind to Plm, it binds specifically to Plg via competing with SK for 
Plg. It remains to be determined experimentally whether the C-terminal domain 
of SIC also binds to the Plg KR5 and/or the SP domains like SK, as discussed 
previously.
Figure 7. 
(a) Streptococcal inhibitor of complement (SIC), a multifunctional protein, binds to a number of proteins 
and peptides that are involved in the formation of membrane attack complex [83], activation of contact 
system [95], antimicrobial activities [96], and clot formation and fibrinolysis [87]. Together, SIC facilitates 
bacterial survival, colonization, and immune evasion. (b) Sequence alignment of SIC from strains M1 and 
M57. Sequence alignment shows variability in the number of repeats in the short repeat region (green), whereas 
the three tandem repeats (1–3) are highly conserved. “*,” “:,” and “.” denote strictly conserved, strongly similar, 
and weakly similar residues, respectively. Alignment was performed using the Clustal Omega multiple sequence 
alignment server (EMBL-EBI). Protein sequence GenBank accession numbers M1, AAK34693.1; M1 AP1, 
AKG28717.1; and M57, AAP31326.1.
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6. Conclusion
The fibrin network plays a pivotal role in innate immune defense via entrapping 
pathogens within the primary infection sites. GAS infection studies in animals 
have provided strong evidence that GAS has the ability to manipulate the host 
fibrinolytic system at many levels [88, 89]. On one hand, hijacking the host Plg/Plm 
on the bacterial surface has provided an energy-efficient strategy to break down 
the fibrin network during dissemination [55, 57, 90], and this is achieved with the 
aid of PAM. Using GAS strains which express both SK2b and PAM genes, it was 
shown that inactivation of either genes significantly reduces virulence [59]. SIC, 
on the other hand, allows the bacteria to make use of the fibrin network as a shelter 
during the initial colonization phase, and it simultaneously inhibits the comple-
ment system in order to ensure the survival of bacteria in the early infection phase. 
The combined effects of these virulent factors perhaps allow the SIC-expressing M1 
strain to be one of most invasive GAS [91].
GAS has evolved into a formidable pathogen through its millennial of coexis-
tence with human host and natural selection; it is invasive and also evasive through 
manipulating the host immunity with a plethora of virulent factors. The three 
extracellular virulent factors discussed in this review modulate specifically the 
fibrinolytic system via an assembly of Plg modulators. Ironically, these virulence 
factors are capable of outranking the human counterparts in terms of efficiencies 
and affinities. SK, for instance, is the most efficacious Plg activator ever discovered, 
and therefore it was the first therapeutic approved for the treatment of thrombotic 
disorders including myocardial infarction [92] and pulmonary embolism [93]. 
With the increasing prevalence of antibiotic-resistant superbugs, GAS infection 
is expected to post a risk to public health worldwide. Better understanding on the 
molecular mechanisms of how these virulent factors manipulate the host immunity 
will provide insight on future development of treatments for GAS infection.
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